FBRX
Forte Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.99
+0.00%Oct 8, 2026, 05:00 UTC
ARGENX SE announced positive topline results from its Phase 2 study of FB102 in adults with celiac disease, reporting that the study met its primary endpoint for change from baseline in the Vh:Cd ratio (p=0.0176).
Oct 2, 2026, 12:07 UTC
Celcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.
Aug 27, 2026, 12:50 UTC
argenx completed its acquisition of Forte Biosciences, Inc., adding the anti-CD122 antibody FB102 to its immunology pipeline.
Source:Jul 27, 2026, 05:00 UTC
argenx agreed to acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
Jul 9, 2026, 12:00 UTC
Forte Biosciences announces positive phase 1b clinical trial results for FB102 in vitiligo, showing statistically significant improvement at week 24.
Jun 2, 2026, 00:00 UTC
Forte Biosciences, Inc. elected Steven Kornfeld, Scott Brun, M.D., and Paul A. Wagner, Ph.D. as Class III directors, effective May 29, 2026.